查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1841565

上游生物加工設備市場－全球產業規模、佔有率、趨勢、機會和預測，按產品類型、工作流程、最終用戶、地區和競爭細分，2020-2030 年預測

Upstream Bioprocessing Equipment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Workflow, By End-User, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球上游生物加工設備市場價值為 295.4 億美元，預計到 2030 年將達到 547.6 億美元，預測期內複合年成長率為 10.67%。

市場概況
預測期 2026-2030
2024年市場規模 295.4億美元
2030年市場規模 547.6億美元
2025-2030年複合年成長率 10.67%
成長最快的領域 細胞分離
最大的市場 北美洲

上游生物加工設備市場是指生物製藥製造業的一個細分市場，專注於生物產品開發的初始階段，特別是細胞培養和發酵過程。這包括生物反應器、發酵槽、細胞培養基、過濾系統和混合系統等設備，這些設備對於培養用於生產生物製劑（包括疫苗、單株抗體、荷爾蒙和重組蛋白）的活細胞或微生物至關重要。

受全球對生物製藥、個人化醫療和生物相似藥需求激增的推動，生物製藥市場有望顯著成長。隨著慢性病和生活方式相關健康問題的日益普遍，對有效生物療法的需求也日益迫切，這推動了對上游生產能力的投資。此外，一次性生物反應器、自動化和連續生物製程等技術創新正在簡化生產流程，提高效率，並降低污染風險，而這些在無菌製藥環境中至關重要。

新興經濟體中合約製造組織和生物製藥公司的擴張也推動了市場成長，因為它們能夠以更低的營運成本獲得先進的製造基礎設施。此外，政府以資助生物製劑研究和生物製造基礎設施建設的形式提供的支持，也進一步刺激了產業擴張。此外，結合不銹鋼和一次性組件的混合生物處理系統的日益普及，提供了更大的靈活性和成本效益，對老牌企業和新創公司都具有吸引力。

隨著對工藝可擴展性和集約化的日益關注，以及監管部門對產品品質和工藝標準化的重視，預計將推動企業升級其上游加工能力。隨著生物製劑產品線的擴展和更複雜分子的開發，上游生物加工設備將在確保高產量和可重複生產方面發揮越來越重要的作用。因此，在技術進步、生物製劑產量成長以及對經濟高效且可擴展的生物製造解決方案的需求的推動下，預計上游生物加工設備市場將在已開發地區和發展中地區實現強勁成長。

關鍵市場促進因素

生物製藥需求不斷成長

主要市場挑戰

高昂的資本投資和營運成本

主要市場趨勢

一次性技術在上游生物加工設備中的整合

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球上游生物加工設備市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依產品類型（生物反應器/發酵槽、細胞培養容器、過濾系統、混合系統、採樣系統、其他）
    • 依工作流程（培養基製備、細胞培養、細胞分離）
    • 按最終用戶（製藥和生物技術公司、合約製造組織、學術和研究機構）
    • 按地區（北美、歐洲、南美、中東和非洲、亞太地區）
  • 按公司分類（2024 年）
  • 市場地圖

第6章：北美上游生物加工設備市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲上游生物加工設備市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太上游生物加工設備市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲上游生物加工設備市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲上游生物加工設備市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如有）
  • 最新動態

第13章：公司簡介

  • Sartorius AG
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Merck KGaA
  • Eppendorf AG
  • ZETA GmbH
  • PBS Biotech, Inc.
  • Thermogenics Inc.
  • Pierre Guerin Technologies
  • Bioengineering AG

第 14 章：策略建議

第15章調查會社について,免責事項

簡介目錄
Product Code: 30259

Global Upstream Bioprocessing Equipment Market was valued at USD 29.54 billion in 2024 and is expected to reach USD 54.76 billion by 2030 with a CAGR of 10.67% during the forecast period.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 29.54 Billion
Market Size 2030USD 54.76 Billion
CAGR 2025-203010.67%
Fastest Growing SegmentCell Separation
Largest MarketNorth America

The Upstream Bioprocessing Equipment Market refers to the segment of the biopharmaceutical manufacturing industry that focuses on the initial phases of biological product development, particularly cell culture and fermentation processes. This includes equipment such as bioreactors, fermenters, cell culture media, filtration systems, and mixing systems that are essential for cultivating living cells or microorganisms used to produce biologics, including vaccines, monoclonal antibodies, hormones, and recombinant proteins.

The market is poised for significant growth driven by the surging global demand for biopharmaceuticals, personalized medicine, and biosimilars. As the prevalence of chronic diseases and lifestyle-related health issues increases, the need for effective biologic therapies is becoming more urgent, propelling investment in upstream manufacturing capacities. Furthermore, technological innovations such as single-use bioreactors, automation, and continuous bioprocessing are streamlining production workflows, enhancing efficiency, and reducing contamination risks, which are vital considerations in sterile pharmaceutical environments.

The expansion of contract manufacturing organizations and biopharmaceutical companies in emerging economies is also fueling market growth by enabling access to advanced manufacturing infrastructure at lower operational costs. In addition, government support in the form of funding for biologics research and biomanufacturing infrastructure development is further stimulating industry expansion. Moreover, increased adoption of hybrid bioprocessing systems that combine stainless steel and disposable components is offering greater flexibility and cost-efficiency, appealing to both established players and startups.

The growing focus on process scalability and intensification, along with regulatory emphasis on product quality and process standardization, is expected to push companies toward upgrading their upstream processing capabilities. As biologic pipelines expand and more complex molecules are developed, upstream bioprocessing equipment will play an increasingly critical role in ensuring high-yield and reproducible production. As a result, the upstream bioprocessing equipment market is anticipated to witness robust growth across developed and developing regions, driven by technological advancements, rising biologics production, and the need for cost-effective and scalable biomanufacturing solutions.

Key Market Drivers

Rising Demand for Biopharmaceuticals

The increasing global demand for biopharmaceuticals, such as monoclonal antibodies, vaccines, and gene therapies, is a primary driver for the Upstream Bioprocessing Equipment Market. The surge in chronic diseases like cancer, diabetes, and autoimmune disorders, coupled with an aging population, has escalated the need for advanced biologics. Upstream bioprocessing equipment, including bioreactors and cell culture systems, is critical for producing these complex therapies at scale.

Governments and healthcare organizations worldwide are prioritizing biopharmaceutical development to address public health challenges, particularly following global health crises like the COVID-19 pandemic, which highlighted the urgency for rapid vaccine production. The shift toward personalized medicine and targeted therapies further amplifies the demand for flexible and scalable bioprocessing solutions. Equipment such as single-use bioreactors enables manufacturers to meet diverse production needs while minimizing contamination risks.

Additionally, emerging markets in Asia-Pacific and Latin America are witnessing increased investments in biopharmaceutical infrastructure, driven by rising healthcare expenditures and growing prevalence of chronic conditions. The ability of upstream equipment to support high-yield cell cultures and recombinant protein production is vital for meeting this demand. As biopharmaceutical companies expand their pipelines to include novel biologics, the Upstream Bioprocessing Equipment Market is poised for sustained growth, fueled by the need for efficient, high-quality production systems that align with stringent regulatory standards and support global health initiatives.

In 2023, global biopharmaceutical production reached 1.2 million liters, with monoclonal antibodies accounting for 45% of output, per the International Federation of Pharmaceutical Manufacturers. Upstream equipment supported 60% of this capacity, with single-use systems contributing to 25% of production. In 2022, vaccine production surged by 30% globally, with bioreactors enabling 2 billion doses, addressing 15% of global demand, particularly in Asia-Pacific, where 200 new facilities were established.

Key Market Challenges

High Capital Investment and Operational Costs

One of the most significant challenges facing the upstream bioprocessing equipment market is the high capital investment required for the installation, commissioning, and validation of biomanufacturing infrastructure. Establishing a biologics manufacturing facility equipped with upstream processing equipment such as bioreactors, centrifuges, media preparation systems, and filtration units involves substantial upfront costs, which can be a barrier for small and mid-sized enterprises. In addition to equipment procurement, expenses related to facility design, utility setup, cleanroom construction, and compliance with regulatory requirements considerably increase the financial burden.

Moreover, the cost of operation is also high due to the need for specialized labor, ongoing maintenance, and frequent calibration of equipment to maintain sterility and productivity. Companies operating in this space must also invest significantly in workforce training and certification to ensure operational proficiency and quality control. While some larger biopharmaceutical companies can absorb these costs due to their expansive budgets and economies of scale, emerging firms and startups often face difficulties in securing adequate funding.

This financial barrier may hinder innovation and delay the time-to-market for critical biologics, especially in regions where public and private investment in biomanufacturing is still limited. The high cost of implementing advanced technologies such as automation, real-time monitoring systems, and single-use components further exacerbates the challenge, particularly for firms seeking cost-efficiency in production.

As the demand for scalable and flexible production systems increases, stakeholders in the upstream bioprocessing equipment market must explore alternative funding models, government grants, and collaborative partnerships to overcome the financial constraints associated with capital investment and operational expenses.

Key Market Trends

Integration of Single-Use Technologies in Upstream Bioprocessing Equipment

The global Upstream Bioprocessing Equipment Market is witnessing a transformative shift with the rapid integration of single-use technologies in bioprocessing workflows. Single-use systems, which include bioreactors, mixers, tubing, and filtration units, are increasingly replacing traditional stainless-steel systems. This trend is particularly driven by the advantages these technologies offer in terms of operational flexibility, reduced contamination risk, and shorter turnaround time between production cycles. In research and development environments, as well as early-phase biologics manufacturing, single-use systems facilitate faster experimentation and scale-up processes without the extensive cleaning and validation requirements of reusable equipment.

Pharmaceutical and biotechnology companies are investing heavily in modular single-use platforms that enable rapid configuration and adjustment based on batch size or biologic type. These platforms allow for high levels of customization, making them suitable for the production of personalized medicines and monoclonal antibodies. Additionally, the reduced capital investment needed for single-use systems appeals to emerging biopharmaceutical firms and contract manufacturing organizations.

Environmental concerns associated with disposability are being addressed through improved material science, with manufacturers developing recyclable or biodegradable single-use components. The growing acceptance of these sustainable options is further accelerating adoption. Regulatory bodies are also becoming more familiar with single-use equipment validation protocols, contributing to their widespread market integration.

As a result, single-use technologies are transforming upstream operations by simplifying workflows, minimizing cross-contamination, and enabling rapid bioprocessing innovation, thereby contributing significantly to the growth of the Upstream Bioprocessing Equipment Market.

Key Market Players

  • Sartorius AG
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Merck KGaA
  • Eppendorf AG
  • ZETA GmbH
  • PBS Biotech, Inc.
  • Thermogenics Inc.
  • Pierre Guerin Technologies
  • Bioengineering AG

Report Scope:

In this report, the Global Upstream Bioprocessing Equipment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Upstream Bioprocessing Equipment Market, By Product Type:

  • Bioreactors/Fermenters
  • Cell Culture Vessels
  • Filtration Systems
  • Mixing Systems
  • Sampling Systems
  • Others

Upstream Bioprocessing Equipment Market, By Workflow:

  • Media Preparation
  • Cell Culture
  • Cell Separation

Upstream Bioprocessing Equipment Market, By End-User:

  • Pharmaceutical and Biotechnology Companies
  • Contract Manufacturing Organizations
  • Academic and Research Institutes

Upstream Bioprocessing Equipment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Upstream Bioprocessing Equipment Market.

Available Customizations:

Global Upstream Bioprocessing Equipment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Upstream Bioprocessing Equipment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Bioreactors/Fermenters, Cell Culture Vessels, Filtration Systems, Mixing Systems, Sampling Systems, Others)
    • 5.2.2. By Workflow (Media Preparation, Cell Culture, Cell Separation)
    • 5.2.3. By End-User (Pharmaceutical and Biotechnology Companies, Contract Manufacturing Organizations, Academic and Research Institutes)
    • 5.2.4. By Region (North America, Europe, South America, Middle East & Africa, Asia Pacific)
  • 5.3. By Company (2024)
  • 5.4. Market Map

6. North America Upstream Bioprocessing Equipment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Workflow
    • 6.2.3. By End-User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Upstream Bioprocessing Equipment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Workflow
        • 6.3.1.2.3. By End-User
    • 6.3.2. Canada Upstream Bioprocessing Equipment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Workflow
        • 6.3.2.2.3. By End-User
    • 6.3.3. Mexico Upstream Bioprocessing Equipment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Workflow
        • 6.3.3.2.3. By End-User

7. Europe Upstream Bioprocessing Equipment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Workflow
    • 7.2.3. By End-User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Upstream Bioprocessing Equipment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Workflow
        • 7.3.1.2.3. By End-User
    • 7.3.2. France Upstream Bioprocessing Equipment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Workflow
        • 7.3.2.2.3. By End-User
    • 7.3.3. United Kingdom Upstream Bioprocessing Equipment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Workflow
        • 7.3.3.2.3. By End-User
    • 7.3.4. Italy Upstream Bioprocessing Equipment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Workflow
        • 7.3.4.2.3. By End-User
    • 7.3.5. Spain Upstream Bioprocessing Equipment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Workflow
        • 7.3.5.2.3. By End-User

8. Asia Pacific Upstream Bioprocessing Equipment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Workflow
    • 8.2.3. By End-User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Upstream Bioprocessing Equipment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Workflow
        • 8.3.1.2.3. By End-User
    • 8.3.2. India Upstream Bioprocessing Equipment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Workflow
        • 8.3.2.2.3. By End-User
    • 8.3.3. Japan Upstream Bioprocessing Equipment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Workflow
        • 8.3.3.2.3. By End-User
    • 8.3.4. South Korea Upstream Bioprocessing Equipment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Workflow
        • 8.3.4.2.3. By End-User
    • 8.3.5. Australia Upstream Bioprocessing Equipment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Workflow
        • 8.3.5.2.3. By End-User

9. Middle East & Africa Upstream Bioprocessing Equipment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Workflow
    • 9.2.3. By End-User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Upstream Bioprocessing Equipment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Workflow
        • 9.3.1.2.3. By End-User
    • 9.3.2. UAE Upstream Bioprocessing Equipment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Workflow
        • 9.3.2.2.3. By End-User
    • 9.3.3. South Africa Upstream Bioprocessing Equipment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Workflow
        • 9.3.3.2.3. By End-User

10. South America Upstream Bioprocessing Equipment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Workflow
    • 10.2.3. By End-User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Upstream Bioprocessing Equipment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Workflow
        • 10.3.1.2.3. By End-User
    • 10.3.2. Colombia Upstream Bioprocessing Equipment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Workflow
        • 10.3.2.2.3. By End-User
    • 10.3.3. Argentina Upstream Bioprocessing Equipment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Workflow
        • 10.3.3.2.3. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends and Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Company Profiles

  • 13.1. Sartorius AG
    • 13.1.1. Business Overview
    • 13.1.2. Key Revenue and Financials
    • 13.1.3. Recent Developments
    • 13.1.4. Key Personnel
    • 13.1.5. Key Product/Services Offered
  • 13.2. Thermo Fisher Scientific Inc.
  • 13.3. Danaher Corporation
  • 13.4. Merck KGaA
  • 13.5. Eppendorf AG
  • 13.6. ZETA GmbH
  • 13.7. PBS Biotech, Inc.
  • 13.8. Thermogenics Inc.
  • 13.9. Pierre Guerin Technologies
  • 13.10. Bioengineering AG

14. Strategic Recommendations

15. About Us & Disclaimer